IBDEI0PU ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12377,0)
 ;;=V25.42^^62^738^51
 ;;^UTILITY(U,$J,358.3,12377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12377,1,3,0)
 ;;=3^V25.42
 ;;^UTILITY(U,$J,358.3,12377,1,4,0)
 ;;=4^IUD Surveillance
 ;;^UTILITY(U,$J,358.3,12377,2)
 ;;=^295350
 ;;^UTILITY(U,$J,358.3,12378,0)
 ;;=V25.43^^62^738^52
 ;;^UTILITY(U,$J,358.3,12378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12378,1,3,0)
 ;;=3^V25.43
 ;;^UTILITY(U,$J,358.3,12378,1,4,0)
 ;;=4^Implant Contraceptive
 ;;^UTILITY(U,$J,358.3,12378,2)
 ;;=^295351
 ;;^UTILITY(U,$J,358.3,12379,0)
 ;;=V25.5^^62^738^89
 ;;^UTILITY(U,$J,358.3,12379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12379,1,3,0)
 ;;=3^V25.5
 ;;^UTILITY(U,$J,358.3,12379,1,4,0)
 ;;=4^Subdermal Contraceptive
 ;;^UTILITY(U,$J,358.3,12379,2)
 ;;=^295352
 ;;^UTILITY(U,$J,358.3,12380,0)
 ;;=V26.51^^62^738^91
 ;;^UTILITY(U,$J,358.3,12380,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12380,1,3,0)
 ;;=3^V26.51
 ;;^UTILITY(U,$J,358.3,12380,1,4,0)
 ;;=4^Tubal Ligation Status
 ;;^UTILITY(U,$J,358.3,12380,2)
 ;;=^321178
 ;;^UTILITY(U,$J,358.3,12381,0)
 ;;=614.0^^62^738^9
 ;;^UTILITY(U,$J,358.3,12381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12381,1,3,0)
 ;;=3^614.0
 ;;^UTILITY(U,$J,358.3,12381,1,4,0)
 ;;=4^Acute Salpingitis and Oophoritis
 ;;^UTILITY(U,$J,358.3,12381,2)
 ;;=^270465
 ;;^UTILITY(U,$J,358.3,12382,0)
 ;;=614.1^^62^738^22
 ;;^UTILITY(U,$J,358.3,12382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12382,1,3,0)
 ;;=3^614.1
 ;;^UTILITY(U,$J,358.3,12382,1,4,0)
 ;;=4^Chr Salpingitis and Oophoritis
 ;;^UTILITY(U,$J,358.3,12382,2)
 ;;=^270466
 ;;^UTILITY(U,$J,358.3,12383,0)
 ;;=616.2^^62^738^28
 ;;^UTILITY(U,$J,358.3,12383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12383,1,3,0)
 ;;=3^616.2
 ;;^UTILITY(U,$J,358.3,12383,1,4,0)
 ;;=4^Cyst of Bartholin Gland
 ;;^UTILITY(U,$J,358.3,12383,2)
 ;;=^12754
 ;;^UTILITY(U,$J,358.3,12384,0)
 ;;=616.3^^62^738^5
 ;;^UTILITY(U,$J,358.3,12384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12384,1,3,0)
 ;;=3^616.3
 ;;^UTILITY(U,$J,358.3,12384,1,4,0)
 ;;=4^Abscess of Bartholin Gland
 ;;^UTILITY(U,$J,358.3,12384,2)
 ;;=^12748
 ;;^UTILITY(U,$J,358.3,12385,0)
 ;;=616.4^^62^738^6
 ;;^UTILITY(U,$J,358.3,12385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12385,1,3,0)
 ;;=3^616.4
 ;;^UTILITY(U,$J,358.3,12385,1,4,0)
 ;;=4^Abscess of Vulva
 ;;^UTILITY(U,$J,358.3,12385,2)
 ;;=^270476
 ;;^UTILITY(U,$J,358.3,12386,0)
 ;;=617.0^^62^738^40
 ;;^UTILITY(U,$J,358.3,12386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12386,1,3,0)
 ;;=3^617.0
 ;;^UTILITY(U,$J,358.3,12386,1,4,0)
 ;;=4^Endometriosis of Uterus
 ;;^UTILITY(U,$J,358.3,12386,2)
 ;;=^270482
 ;;^UTILITY(U,$J,358.3,12387,0)
 ;;=617.2^^62^738^39
 ;;^UTILITY(U,$J,358.3,12387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12387,1,3,0)
 ;;=3^617.2
 ;;^UTILITY(U,$J,358.3,12387,1,4,0)
 ;;=4^Endometriosis of Fallopian Tube
 ;;^UTILITY(U,$J,358.3,12387,2)
 ;;=^40475
 ;;^UTILITY(U,$J,358.3,12388,0)
 ;;=620.0^^62^738^47
 ;;^UTILITY(U,$J,358.3,12388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12388,1,3,0)
 ;;=3^620.0
 ;;^UTILITY(U,$J,358.3,12388,1,4,0)
 ;;=4^Follicular cyst of ovary
 ;;^UTILITY(U,$J,358.3,12388,2)
 ;;=^47322
 ;;^UTILITY(U,$J,358.3,12389,0)
 ;;=620.1^^62^738^27
 ;;^UTILITY(U,$J,358.3,12389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12389,1,3,0)
 ;;=3^620.1
 ;;^UTILITY(U,$J,358.3,12389,1,4,0)
 ;;=4^Corpus luteum cyst or hematoma
 ;;^UTILITY(U,$J,358.3,12389,2)
 ;;=^270508
 ;;^UTILITY(U,$J,358.3,12390,0)
 ;;=620.8^^62^738^62
 ;;^UTILITY(U,$J,358.3,12390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12390,1,3,0)
 ;;=3^620.8
 ;;
 ;;$END ROU IBDEI0PU
